| 9741/13381 | US=67 / Biol/Mol Perales MA, Wolchok JD, Kaufman HL. Vaccines as targeted cancer therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 447-69. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. |
| 9742/13381 | US=67 / Biol/Mol Koon HB, Atkins MB. Cytokine-based therapy for cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 471-507. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER. TERAPIA; CITOQUINA; INTERFERON; INTERLEUCINA; IMUNOTERAPIA; RESISTENCIA; LEUCEMIA DE CELULAS PILOSAS; LEUCEMIA MIELOIDE CRONICA; LINFOMA NAO-HODGKIN; MELANOMA; CARCINOMA DE CELULAS RENAIS; SARCOMA DE KAPOSI |
| 9743/13381 | US=67 / Biol/Mol Bertagnolli M, Viner JL, Hawk ET. Cyclooxygenase-2 as a target for cancer prevention and treatment. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 509-41. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CICLOOXIGENASE-2; COX-2; CANCER. PREVENCAO; CANCER. TRATAMENTO; INFLAMACAO; PROSTAGLANDINA; TUMORIGENESE |
| 9744/13381 | US=67 / Biol/Mol Denis GV. Imatinib mesylate (gleevec) and the emergence of chemotherapeutic drug-resistant mutations. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 545-57. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. QUIMIOTERAPICOS; MUTACOES; RESISTENCIA AOS MEDICAMENTOS; MESILATO DE IMATINIBE; GLEEVEC; STI-571; LEUCEMIA MIELOGENA CRONICA; TUMOR ESTROMAL GASTROINTESTINAL; BCR-ABL; C-KIT; FATOR DE CELULA-TRONCO; BIOLOGIA ESTRUTURAL |
| 9745/13381 | US=67 / Biol/Mol Mendelsohn J. Development of a targeted treatment for cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 559-71. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER; TERAPIA; FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; CETUXIMABE; TIROSINA QUINASE; ANTICORPO MONOCLONAL C225 |
| 9746/13381 | US=67 / Biol/Mol Saini S, Hurwitz H. VEGF inhibition for cancer therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 573-84. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. INIBICAO DO VEGF; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; TERAPIA DO CANCER; ANTI-ANGIOGENESE; INIBICAO DA QUINASE DE TIROSINA; BEVACIZUMABE; SORAFENIBE; BAY 43-9006; MALATO DE SUNITINIBE; SU11248; VATALANIBE |
| 9747/13381 | US=67 / Biol/Mol Champaneria MC, Modlin IM, Latich I, Bornschein J, Drozdov I, Kidd M. Somatostatin analogue therapy. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 585-637. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. TERAPIA ANALOGA DA SOMATOSTATINA; ACROMEGALIA; CARCINOIDE; SINDROME CARCINOIDE; HORMONIO DE CRESCIMENTO; LUTECIO; OCTREOTIDE; NEUROENDOCRINO; PROLIFERACAO; CINTILOGRAFIA; RECEPTOR DE SOMATOSTATINA; SOMATULINA; TUMOR; ITRIO |
| 9748/13381 | US=67 / Biol/Mol Dy GK, Adjei AA. Patient selection for rational development of novel anticancer agents. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 641-8. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. AGENTES ANTICANCERIGENOS; SELECAO DOS PACIENTES; TERAPIA-ALVO; BIOMARCADORES; EXPRESSAO GENICA; AMPLIFICACAO GENICA |
| 9749/13381 | US=67 / Biol/Mol Dubey S, Schiller JH. Clinical trial design with targeted agents. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 649-55. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. ESTUDO CLINICO; AGENTES DIRECIONADOS; ENSAIOS CLINICOS; AGENTES ALVOS |
| 9750/13381 | US=67 / Biol/Mol Kitzen JJEM, de Jonge MJA, Verweij J. How to define treatment sucess or failure if tumors do not shrink: consequences for trial design. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 657-74. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. MARCADOR SUBSTITUTO; TECIDO SUBSTITUTO; RECEPTOR DE FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; INIBIDOR DA FARNESIL TRANSFERASE; SELECAO DE PACIENTE; IMAGEM; PROJETO DESCONTINUACAO RANDOMIZADO; INDICE DE MODULACAO DO CRESCIMENTO; TAXA DE PROGRESSAO; TAXA LIVRE DE PROGRESSAO |
| 9751/13381 | US=67 / Biol/Mol Shankar LK, Menkens A, Sullivan DC. Molecular imaging in oncology. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 675-91. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. ONCOLOGIA; IMAGEM MOLECULAR; BIOMARCADORES DE IMAGEM; BIOMARCADORES IN VIVO; TESTES DE CANCER; PROCESSO NEOPLASICO; AGENTES PET; CONTRASTE AGENTES MR; TECNOLOGIA OPTICA |
| 9752/13381 | US=67 / Biol/Mol Chen HX, Dancey JE. Combinations of molecular-targeted therapies: opportunities and challenges. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 693-705. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. |
| 9753/13381 | US=67 / Biol/Mol Tomaszewski JE, Doroshow JH. Preclinical development of molecularly targeted agents in oncology. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 707-22. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. ONCOLOGIA; DESENVOLVIMENTO PRE-CLINICO; AGENTES ALVO MOLECULARES; AGENTES ANTITUMORAIS; DESENVOLVIMENTO DE DROGAS; ALVOS MOLECULARES; FARMACOCINETICA; FARMACODINAMICA; TOXICOLOGIA |
| 9754/13381 | US=67 / Imagem Murphy PS, Roychowdhury D. Incorporating imaging into drug development: and industry perspective. In: Mulshine JL, Baer TM. Quantitative imaging tools for lung cancer drug assessment. New Jersey: John Wiley & Sons, 2008. p. 1-15. ISBN 978-0-470-11880-1. CANCER DE PULMAO; IMAGEM; DESENVOLVIMENTO DE DROGAS; BIOMARCADORES; ENSAIOS CLINICOS |
| 9755/13381 | US=67 / Imagem Dziadziuszko R, Hirsch FR, Bunn Junior PA. Advances in lung cancer treatment. In: Mulshine JL, Baer TM. Quantitative imaging tools for lung cancer drug assessment. New Jersey: John Wiley & Sons, 2008. p. 17-37. ISBN 978-0-470-11880-1. CANCER DE PULMAO; TERAPIA; CARCINOMA DE PULMAO DE NAO-PEQUENAS CELULAS; TRATAMENTO PALIATIVO; CARCINOMA DE PULMAO DE PEQUENAS CELULAS |
| 9756/13381 | US=67 / Imagem Avila RS. Quantitative imaging in CT lung cancer drug development and evaluation. In: Mulshine JL, Baer TM. Quantitative imaging tools for lung cancer drug assessment. New Jersey: John Wiley & Sons, 2008. p. 39-51. ISBN 978-0-470-11880-1. CANCER DE PULMAO; IMAGENS QUANTITATIVAS; TOMOGRAFIA COMPUTADORIZADA; DESENVOLVIMENTO DE DROGAS |
| 9757/13381 | US=67 / Imagem Zhao B, Schwartz LH. Volumetric ct imaging for response assessment in lung cancer: a platform for translational research. In: Mulshine JL, Baer TM. Quantitative imaging tools for lung cancer drug assessment. New Jersey: John Wiley & Sons, 2008. p. 53-66. ISBN 978-0-470-11880-1. CANCER DE PULMAO; TOMOGRAFIA COMPUTADORIZADA VOLUMETRICA; PESQUISA TRANSLACIONAL; APLICACOES INFORMATICAS |
| 9758/13381 | US=67 / Imagem Pearson J, Tarbox L, Paladini G, Wolodzko JG, Jacobs PM, Lee Z. Emerging radiological software standards and development technologies: impact on clinical translation and trials. In: Mulshine JL, Baer TM. Quantitative imaging tools for lung cancer drug assessment. New Jersey: John Wiley & Sons, 2008. p. 67-93. ISBN 978-0-470-11880-1. PADROES RADIOLOGICOS EMERGENTES; SOFTWARE; TECNOLOGIAS DE DESENVOLVIMENTO; TRADUCAO; ENSAIOS CLINICOS |
| 9759/13381 | US=67 / Imagem Mazumdar M, Zhou XK. Statistical considerations underlying therapeutic response criteria for lung cancer: multislice ct scanners and cad algorithms for volumetric assessment. In: Mulshine JL, Baer TM. Quantitative imaging tools for lung cancer drug assessment. New Jersey: John Wiley & Sons, 2008. p. 95-109. ISBN 978-0-470-11880-1. CANCER DE PULMAO; CONSIDERACOES ESTATISTICAS SUBJACENTES; CRITERIOS DE RESPOSTA TERAPEUTICAS; TOMOGRAFIA MULTISLICE SCANNERS; ALGORITMOS DE CAD; AVALIACAO VOLUMETRICA |
| 9760/13381 | US=67 / Imagem Baer TM, Clark CW, Karam L. Programs supporting quantitative imaging in biomedicine at the national institute of standards and technology. In: Mulshine JL, Baer TM. Quantitative imaging tools for lung cancer drug assessment. New Jersey: John Wiley & Sons, 2008. p. 111-22. ISBN 978-0-470-11880-1. CANCER DE PULMAO; PROGRAMAS DE APOIO; IMAGENS QUANTITATIVAS; BIOMEDICINA; INSTITUTO NACIONAL DE PADROES E TECNOLOGIA |